

# Canagliflozin REnal Distribution Intervention Trial (CREDIT)

No registrations found.

<b>Ethical review</b>	Not applicable
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON26995

### Source

Nationaal Trial Register

### Brief title

CREDIT

### Health condition

Type 2 diabetes mellitus

## Sponsors and support

**Primary sponsor:** University Medical Center Groningen

**Source(s) of monetary or material Support:** ZonMw and Diabetes Fonds

## Intervention

## Outcome measures

### Primary outcome

The main study parameters are dynamic PET data and images and radiation count measurement, and free plasma concentrations of canagliflozin.

### Secondary outcome

The secondary study parameters are (estimated) Glomerular Filtration Rate, plasma glucose and urine glucose excretion

## Study description

### Background summary

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs used in the treatment of type 2 diabetes mellitus and they have shown to slow progression of diabetic kidney disease and to have beneficial effects on cardiovascular end points, in particular reduction of heart failure. However, the response of SGLT2 inhibitors on albuminuria and eGFR varies between individuals and about 20% of patients does not respond at all. Consequently, a considerable proportion of patients remain at high risk of progressive renal function loss. We hypothesize that the variability in drug response between individuals is the result of between individual variability in drug disposition to target tissues. To test this hypothesis we have synthesized an <sup>18</sup>F PET radiotracer of the SGLT2 inhibitor canagliflozin, retaining the original molecular structure. As a first step, we will evaluate <sup>18</sup>F-canagliflozin receptor specific binding, receptor occupancy, and optimal PET scanning time. As such, in this clinical feasibility study, we will generate essential PET data to optimize the design of a future clinical study in subjects with type 2 diabetes and microvascular complications.

### Study objective

We hypothesize that the underlying mechanisms of the varying response to a drug in multiple parameters within an individual can be attributed to variability in the causal path between drug administration, drug tissue distribution, and tissue receptor interaction.

In this clinical feasibility study we will assess radiolabeled canagliflozin pharmacokinetic characteristics and determine specific receptor binding, receptor occupancy and optimal scanning time in patients with diabetes. The main objectives are;

To assess canagliflozin target (i.e. receptor) specific binding in vivo

To assess receptor occupancy of canagliflozin in vivo

### Study design

During both study days, for all patients, after radiotracer drug administration, arterial plasma samples will be taken obtained by an automated sampler for radioactivity in full blood and plasma. After administration of oral canagliflozin 11 venous blood samples will be obtained for canagliflozin PK assessment. 24-hour urine will be collected for the measurement of 24-h glucose, protein, albumin, sodium, potassium, creatinine, and urea excretion at both study days. Plasma glucose will be measured after oral canagliflozin administration.

## Intervention

On the first study day, a non-diagnostic dose CT scan will be performed to optimally position the individual patient for the dynamic PET scan (e.g. with kidney, aorta and part of the liver inside the field of view) and attenuation correction, respectively. At time=0, patients will receive an intravenous diagnostic dose of 200Mbq <sup>18</sup>F canagliflozin radiotracer followed by a 90-minute dynamic PET scan. At the second visit patients will receive an oral dose of 50, 100 or 300 mg canagliflozin (3 patients per dose group). At the approximate time of maximal plasma canagliflozin concentration (t<sub>max</sub>, t=2.5h) a second intravenous radiotracer dose will be administered immediately followed by a second 90-minute dynamic PET scan. In this second scan, receptor binding sites are occupied by canagliflozin, hence the reduction of radiotracer uptake compared to the baseline scan can be used to determine the receptor occupancy based on the binding potentials obtained from both scans. In all patients arterial plasma samples will be taken after radiotracer administration, to quantify radiation measures of <sup>18</sup>F canagliflozin and its metabolites and venous blood samples will be taken after oral canagliflozin administration to obtain plasma concentrations of canagliflozin.

## Contacts

### Public

Universitair Medisch Centrum Groningen  
Hiddo Lambers Heerspink

050-361 7859

### Scientific

Universitair Medisch Centrum Groningen  
Hiddo Lambers Heerspink

050-361 7859

## Eligibility criteria

### Inclusion criteria

Type 2 diabetes  
Age ≥ 40 years <75 years  
Written informed consent

## Exclusion criteria

- Pregnant women and women of child-bearing potential who are not using reliable contraception
- eGFR < 30 mL/min/1.73 m<sup>2</sup>
- Subjects on diuretics are allowed to participate but the dose should be stable for at least 4 weeks prior to screening
- Subjects already on a SGLT2 inhibitor are allowed to participate, but the drug should be interrupted 1 week prior to the first study day till the end of the second study day
- Subjects using a sulphonylurea.
- Established peripheral arterial disease
- Cardiovascular disease: myocardial infarction, angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, stroke, heart failure (NYHA I-IV) < 3 months before inclusion
- History of hypersensitivity to canagliflozin or another SGLT2 inhibitor
- Active malignancy
- Donation or loss of 400 ml or more of blood within 8 weeks prior to initial dosing
- History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.
- Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following:

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

### Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-12-2020
Enrollment:	9
Type:	Anticipated

## IPD sharing statement

**Plan to share IPD:** Undecided

## Ethics review

Not applicable

Application type: Not applicable

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 50114

Bron: ToetsingOnline

Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL7707
CCMO	NL70157.042.19
OMON	NL-OMON50114

## Study results